CTSD — Cathepsin D

Migration, Crosslink

📖

CTSD — Cathepsin D

active

wiki page Created: 2026-04-02T07:19:18 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-catheapsin-d

📖 Wiki Page

gene2576 wordssynced 2026-04-02

CTSD — Cathepsin D

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CTSD — Cathepsin D</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CTSD</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cathepsin D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1509</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>116840</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000103811</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P07339</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>412 amino acids (preproenzyme)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa (prepro), 31 kDa (mature)</td>
</tr>
<tr>
<td class="label">Enzyme Classification</td>
<td>EC 3.4.23.5 (aspartyl protease)</td>
</tr>
</table>

Overview

CTSD (Cathepsin D) encodes a lysosomal aspartyl endopeptidase that is a central player in protein degradation, autophagy-lysosomal function, and cellular homeostasis in the brain. Cathepsin D is synthesized as a preproenzyme (52 kDa) that undergoes sequential proteolytic processing: signal peptide removal in the ER, removal of the propeptide in the late endosome/lysosome to generate the mature active enzyme composed of a light chain (14 kDa) and heavy chain (31 kDa) heterodimer[@qiu2022].

...

CTSD — Cathepsin D

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CTSD — Cathepsin D</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CTSD</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cathepsin D</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>11p15.5</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1509</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>116840</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000103811</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P07339</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>412 amino acids (preproenzyme)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa (prepro), 31 kDa (mature)</td>
</tr>
<tr>
<td class="label">Enzyme Classification</td>
<td>EC 3.4.23.5 (aspartyl protease)</td>
</tr>
</table>

Overview

CTSD (Cathepsin D) encodes a lysosomal aspartyl endopeptidase that is a central player in protein degradation, autophagy-lysosomal function, and cellular homeostasis in the brain. Cathepsin D is synthesized as a preproenzyme (52 kDa) that undergoes sequential proteolytic processing: signal peptide removal in the ER, removal of the propeptide in the late endosome/lysosome to generate the mature active enzyme composed of a light chain (14 kDa) and heavy chain (31 kDa) heterodimer[@qiu2022].

Cathepsin D is one of the most abundant lysosomal proteases and is essential for the degradation of long-lived proteins, organelles (mitophagy), and the clearance of pathological protein aggregates. It plays a dual role in neurodegeneration: under normal conditions, it protects neurons by clearing toxic proteins; under pathological conditions, its dysregulation contributes to neuronal death through excessive protease activity, lysosomal membrane permeabilization, and altered processing of disease-relevant substrates[@stoka2021].

Mutations in CTSD cause neuronal ceroid lipofuscinosis type 10 (CLN10), a severe early-onset neurodegenerative storage disorder. Beyond monogenic disease, cathepsin D activity and expression are altered in Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS), making it both a disease biomarker and a therapeutic target[@qiu2022].

Gene and Protein Structure

Protein Architecture

Cathepsin D adopts the classical pepsin-like bilobal structure with two homologous domains:

N-terminal lobe: Contains the activation peptide (propeptide, ~44 amino acids) that blocks the active site; cleavage of this peptide is required for activation
C-terminal lobe: Contains the second catalytic aspartate residue
Active site: Two conserved aspartate residues (Asp33, Asp231 in human enzyme) that coordinate a water molecule for nucleophilic attack on peptide bonds
Glycosylation: N-linked glycosylation sites (Asn133, Asn271) important for trafficking to lysosomes; mannose-6-phosphate (M6P) tags direct enzyme to lysosomes via M6P receptors
pH optimum: Strongly acidic (pH 3.5-5.0), optimal for lysosomal environment

The mature enzyme consists of a light chain (~14 kDa) and a heavy chain (~31 kDa) generated by auto-cleavage at low pH. The heavy chain contains the main body of the protein while the light chain carries the N-terminal region including part of the active site.

Normal Biological Function

Lysosomal Protein Degradation

Cathepsin D is the most abundant lysosomal protease and is responsible for:

Bulk protein turnover: Degradation of long-lived proteins during normal cellular recycling
Autophagy substrate clearance: Final degradation step for autophagosome cargo after lysosomal fusion
Organelle turnover: Mitophagy (mitochondrial degradation), pexophagy (peroxisome), ribophagy (ribosome)
Protein quality control: Clearing misfolded, aggregated, and damaged proteins

Unlike the proteasome (which degrades ubiquitin-tagged proteins one at a time), cathepsin D handles bulk substrates delivered via autophagy pathways. This makes it essential for neuronal homeostasis given the high metabolic rate and limited replicative capacity of neurons.

Prohormone and Progrowth Factor Activation

Cathepsin D activates several precursor proteins:

Proinsulin: Cathepsin D processes proinsulin to active insulin in pancreatic beta cells
Nerve growth factor (NGF): Pro-NGF is activated by cathepsin D; this is critical for neuronal survival signaling
Procathepsin D: Auto-activation from zymogen to mature enzyme is a self-contained process

Autophagy Regulation

Cathepsin D influences autophagy at multiple levels:

Lysosomal fusion: Regulates SNARE machinery for autophagosome-lysosome fusion
TFEB activation: Cathepsin D activity influences the lysosomal signaling that controls TFEB nuclear translocation
Aggregate clearance: Directly digests protein aggregates delivered by selective autophagy receptors (p62/SQSTM1, NDP52, optineurin)

Role in Alzheimer's Disease

Amyloid-Beta Metabolism

Cathepsin D has a complex, context-dependent relationship with amyloid-beta ([Aβ](/entities/amyloid-beta)) metabolism[@ambrozak2021]:

Degradative Function (Protective):

Cathepsin D degrades both Aβ40 and Aβ42 in vitro and in cell models
Overexpression of cathepsin D reduces extracellular Aβ accumulation in APP transgenic mice
Cathepsin D knockout mice show impaired Aβ clearance and accelerated plaque formation
Human AD brain shows increased cathepsin D activity in affected regions, likely reflecting compensatory upregulation

Generative Function (Pathogenic):

Cathepsin D can cleave [APP](/entities/app-protein) at certain sites, potentially generating amyloidogenic fragments
The balance between amyloidogenic and non-amyloidogenic processing depends on cellular context, pH, and co-localization
In some contexts, cathepsin D may contribute to Aβ production, though this is minor compared to BACE1 and gamma-secretase

Therapeutic Implication:
Given the dual nature, strategies targeting cathepsin D must be carefully designed. Enhancing delivery to lysosomes (avoiding extracellular secretion) or timing activation precisely could shift the balance toward protective degradation.

Tau Pathology

Cathepsin D is involved in [tau](/proteins/tau) metabolism and pathology[@kumar2022]:

Cathepsin D cleaves tau at specific sites, generating truncated fragments with different aggregation properties
Truncated tau fragments generated by cathepsin D can act as seeds for tau aggregation
Lysosomal dysfunction in AD impairs cathepsin D trafficking and activation, leading to proteostasis failure
Cathepsin D activity is inversely correlated with tau phosphorylation in some models, suggesting regulatory crosstalk

Lysosomal Dysfunction in AD

AD is increasingly recognized as a lysosomal storage disorder at the cellular level. Features include:

Endo-lysosomal acidification defects: Vacuolar H+-ATPase dysfunction leads to less acidic lysosomes, impairing cathepsin D activation
Autophagosome-lysosome fusion deficits: Accumulation of autophagosomes with undigested cargo
Lysosomal membrane permeabilization (LMP): In advanced disease, lysosomal rupture releases cathepsin D into cytoplasm, triggering apoptotic cascades
Neuronal lipofuscin accumulation: Age-related accumulation of undegraded material reflects declining cathepsin D function

Neuroinflammation

Cathepsin D in [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes) modulates neuroinflammation[@chen2022]:

Cathepsin D release from activated microglia contributes to inflammatory signaling
Cathepsin D cleaves inflammatory mediators and cytokines
Impaired microglial cathepsin D function leads to defective clearance of cellular debris, perpetuating inflammation
Cathepsin D in astrocytes affects their metabolic support of neurons

Role in Parkinson's Disease

Alpha-Synuclein Clearance

Cathepsin D is a key enzyme for degrading [alpha-synuclein](/proteins/alpha-synuclein) and clearing alpha-synuclein aggregates[@norenberg2022]:

Direct degradation: Cathepsin D cleaves alpha-synuclein at multiple sites, reducing fibril formation
Autophagy flux: Cathepsin D activity is required for autophagic clearance of alpha-synuclein aggregates
Compensatory upregulation: PD substantia nigra shows increased cathepsin D expression, likely as a compensatory response to rising aggregate burden
Impaired delivery: Extracellular alpha-synuclein impairs the trafficking of cathepsin D to lysosomes, creating a feedforward cycle of proteostasis failure[@cheng2023]

Relationship to GBA and Lysosomal PD

Heterozygous [GBA](/genes/gba) mutations are the strongest genetic risk factor for PD. Cathepsin D interacts with the GBA pathway:

GBA deficiency leads to glucosylceramide accumulation, which impairs lysosomal acidification
Reduced acidification decreases cathepsin D activation
This creates a double hit: GBA deficiency impairs cathepsin D, which reduces alpha-synuclein clearance, which is already compromised by GBA loss

PD Substantia Nigra Findings

Studies of human PD substantia nigra demonstrate:

Increased cathepsin D protein and activity in dopaminergic neurons
Altered processing: more procathepsin D and less mature enzyme, suggesting trafficking defects
Co-localization of cathepsin D with alpha-synuclein aggregates in Lewy body-containing neurons
The compensatory increase in cathepsin D may be insufficient to overcome the aggregate burden

Role in Amyotrophic Lateral Sclerosis

TDP-43 Pathology

Cathepsin D is implicated in [TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathy, the hallmark pathology of ALS and frontotemporal dementia[@haim2022]:

TDP-43 aggregates colocalize with lysosomal markers including cathepsin D in ALS motor neurons
Cathepsin D can degrade TDP-43 fragments that form aggregates
Impaired lysosomal function in ALS reduces cathepsin D-mediated TDP-43 clearance
The autophagy-lysosomal pathway is broadly impaired in ALS due to mutations in genes like C9orf72, TARDBP, and OPTN

Motor Neuron Vulnerability

Motor neurons appear particularly sensitive to cathepsin D dysfunction:

ALS motor neurons show accumulation of lysosomal storage material and impaired autophagic flux
Cathepsin D activity is altered in ALS spinal cord
Enhancing cathepsin D or other lysosomal proteases is being explored as a therapeutic strategy for ALS

ALS Genetics Connection

ALS genes affecting lysosomal function:

C9orf72: The most common ALS gene; loss of function impairs autophagy-lysosomal pathway
TBK1: Kinase regulating autophagy receptor phosphorylation and lysosomal function
OPTN: Autophagy receptor that brings cargo to lysosomes
SQSTM1 (p62): Autophagy receptor that delivers aggregates for cathepsin D degradation

All of these pathways converge on the final degradation step performed by cathepsin D.

Neuronal Ceroid Lipofuscinosis Type 10 (CLN10)

Disease Overview

Biallelic mutations in CTSD cause CLN10, one of the most severe forms of neuronal ceroid lipofuscinosis (NCL)[@sunkar2022]:

Onset: Severe, often congenital or early infantile presentation
Core features: Progressive neurodegeneration, seizures, visual impairment, developmental regression
Pathology: Accumulation of ceroid lipofuscin (lysosomal storage material) in neurons and other cell types
MRI: Rapidly progressive brain atrophy, white matter changes

Molecular Mechanism

The pathogenesis of CTSD-CLN10 reflects the critical role of cathepsin D in lysosomal function:

Loss of cathepsin D activity leads to accumulation of undegraded substrates in lysosomes
Ceroid lipofuscin (a complex autofluorescent material from partially degraded lipids and proteins) accumulates
Lysosomal storage triggers endoplasmic reticulum stress, mitochondrial dysfunction, and ultimately apoptosis
The early and severe onset reflects the essential nature of cathepsin D in cellular homeostasis

Diagnosis and Management

Enzyme activity assay: Measure cathepsin D activity in fibroblasts or leukocytes
Genetic testing: Confirm biallelic CTSD mutations
Management: Supportive care for seizures, nutritional support, physical therapy; no disease-modifying treatment available

Therapeutic Strategies

Enhancement of Cathepsin D Activity

Several strategies aim to boost cathepsin D function for neurodegenerative disease:

Small molecule activators: Compounds that promote procathepsin D processing or enhance enzyme stability

Autophagy induction: Rapamycin, lithium, carbamazepine, and other autophagy enhancers increase autophagic flux, delivering more substrate to lysosomes where cathepsin D acts

Lysosomal acidification: Small molecules that restore lysosomal pH (e.g., v-ATPase modulators) would enhance cathepsin D activation

Gene therapy: AAV-mediated CTSD overexpression to enhance lysosomal protease capacity

Cathepsin D Inhibitors

While enhancement seems beneficial, some contexts call for inhibition[@liu2023]:

Cancer: Cathepsin D is overexpressed and secreted by many tumors; inhibitors are being developed as anticancer agents
Autoimmune disease: Extracellular cathepsin D can activate inflammatory pathways; inhibition might reduce neuroinflammation
Caution in neurodegeneration: Systemic inhibition would impair lysosomal function and likely worsen disease

Substrate Reduction Approaches

Since cathepsin D degrades both protective and pathogenic substrates, some approaches focus on reducing the pathogenic load:

BACE1 inhibitors: Reduce Aβ production, relieving the burden on cathepsin D for Aβ clearance
Alpha-synuclein aggregation inhibitors: Reduce the load of difficult-to-degrade aggregates
Anti-aggregation compounds: Enhance the solubility of protein aggregates, making them more accessible to cathepsin D

Expression Patterns

Cathepsin D is expressed in most cell types with particularly high levels in:

Neurons: Especially pyramidal neurons of hippocampus and cortex, cerebellar Purkinje cells
Microglia: High expression in activated microglia; role in neuroinflammation
Astrocytes: Important for astrocyte protein turnover and metabolic support
Liver: Major secretory organ
Kidney: High lysosomal activity in proximal tubule cells

Within the CNS, cathepsin D expression is:

Cytoplasmic: Predominantly lysosomal localization
Neuronal soma: High in cell body; transported to distal compartments
Synaptic terminals: Present in nerve terminals; degradation of synaptic proteins
Glial cells: Distributed throughout glial cytoplasm

Molecular Interactions

Substrates

Cathepsin D cleaves a wide range of substrates including:

APP: Can generate amyloidogenic fragments
Tau: Generates truncated fragments with variable aggregation properties
Alpha-synuclein: Degrades monomeric and oligomeric forms; less effective against fibrils
TDP-43: Cleaves aggregation-prone fragments
Myelin basic protein: Relevance to demyelinating conditions
Cytokines and growth factors: Processing/activation role

Protein Interactions

Cathepsin B: Co-localizes with cathepsin D in lysosomes; often acts together on substrates
LAMP1/LAMP2: Lysosomal membrane proteins that protect cathepsin D from leakage
M6P receptor: Directs procathepsin D trafficking to lysosomes
p62/SQSTM1: Delivers ubiquitinated aggregates to lysosomes for degradation
GBA: Functional crosstalk through lysosomal pH and lipid environment

Biomarker Potential

Cathepsin D has been investigated as a biomarker for neurodegenerative disease[@kim2021]:

CSF cathepsin D: Elevated levels in AD and PD compared to controls
Blood/serum: Less reliable due to contributions from peripheral sources
Activity-based probes: Chemical probes that label active cathepsin D could track enzyme activity in vivo
Limitation: Non-specific elevation in many conditions; not disease-specific

Research Models

Cell Culture

CTSD knockout cells: Complete loss of cathepsin D; severe lysosomal storage phenotype
CTSD knockdown: Partial reduction; models age-related decline
Primary neurons: Mouse cortical/hippocampal neurons for studying neuronal cathepsin D function
iPSC-derived neurons: From patients with CTSD mutations (CLN10) and sporadic disease

Animal Models

Ctsd knockout mice: Perinatal or early postnatal lethality; severe lysosomal storage; used to understand disease mechanisms
Ctsd heterozygous mice: Partial deficiency; model age-related decline
APP/PS1 x Ctsd+/− mice: Cross of AD model with cathepsin D haploinsufficiency; accelerated pathology
Alpha-synuclein transgenic x Ctsd+/− mice: Show worsened alpha-synuclein pathology with reduced cathepsin D

Chemical/Induced Models

MPP+ models: Cathepsin D activity altered in dopaminergic cell models
Rotenone models: Mitochondrial toxins alter lysosomal function and cathepsin D
Lysosomal storage inducers: Compounds that block lysosomal degradation create models of impaired cathepsin D function

External Links

[NCBI Gene: CTSD](https://www.ncbi.nlm.nih.gov/gene/1509)
[OMIM: CTSD](https://www.omim.org/entry/116840)
[UniProt: P07339](https://www.uniprot.org/uniprot/P07339)
[GeneCards: CTSD](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CTSD)
[RCSB PDB: Cathepsin D structures](https://www.rcsb.org/pages/search?target=QS&q=cathepsin+D)
[NCL Resource: CTSD](https://jfchen.ccvisa.net/nclweb/ctsd.html)

References

[Qiu Q, et al. Cathepsin D in neurodegeneration and Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35858832/)

[Stoka V, et al. Lysosomal cathepsins in neuronal death (2021)](https://pubmed.ncbi.nlm.nih.gov/33830333/)

[Sunkar S, et al. CTSD mutations cause neuronal ceroid lipofuscinosis-10 (2022)](https://pubmed.ncbi.nlm.nih.gov/34961973/)

[Ambrozak J, et al. Lysosomal cathepsin D in amyloid-beta metabolism (2021)](https://pubmed.ncbi.nlm.nih.gov/33523020/)

[Norenberg T, et al. Cathepsin D in alpha-synuclein clearance and Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35038471/)

[Haim L, et al. Cathepsin D and TDP-43 pathology in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Cheng N, et al. Extracellular alpha-synuclein impairs lysosomal cathepsin D delivery (2023)](https://pubmed.ncbi.nlm.nih.gov/38163647/)

[Martinez E, et al. Autophagy-lysosomal pathway in Alzheimer's disease and cathepsin D role (2021)](https://pubmed.ncbi.nlm.nih.gov/33935666/)

[Barton B, et al. Targeting cathepsin D for Alzheimer's disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37031247/)

[Chen L, et al. Cathepsin D in neuroinflammation and glial function (2022)](https://pubmed.ncbi.nlm.nih.gov/35194924/)

[Wu L, et al. Cathepsin D deficiency and neurodegeneration: CLN10 lessons (2021)](https://pubmed.ncbi.nlm.nih.gov/34050432/)

[Hernandez M, et al. Procathepsin D processing and lysosomal membrane permeabilization (2023)](https://pubmed.ncbi.nlm.nih.gov/35982091/)

[Zhang Y, et al. Cathepsin D in traumatic brain injury and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32496907/)

[Kim J, et al. Cathepsin D as a biomarker for neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33607820/)

[Liu X, et al. Cathepsin D inhibition and neuroprotection strategies (2023)](https://pubmed.ncbi.nlm.nih.gov/36758742/)

[Steele J, et al. Sphingolipid catabolism and cathepsin D crosstalk in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35472011/)

[Ohno H, et al. Cathepsin D in endosomal-lysosomal trafficking (2021)](https://pubmed.ncbi.nlm.nih.gov/33993308/)

[Kumar S, et al. Cathepsin D in tau pathology and Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35596982/)

📖 View canonical wiki page →

Related Entities

CATHEAPSIND

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-catheapsin-d
kg_node_id	CATHEAPSIND
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-96ef55041733
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-catheapsin-d'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

27

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CTSD — Cathepsin D

CTSD — Cathepsin D

Overview

CTSD — Cathepsin D

Overview

Gene and Protein Structure

Protein Architecture

Normal Biological Function

Lysosomal Protein Degradation

Prohormone and Progrowth Factor Activation

Autophagy Regulation

Role in Alzheimer's Disease

Amyloid-Beta Metabolism

Tau Pathology

Lysosomal Dysfunction in AD

Neuroinflammation

Role in Parkinson's Disease

Alpha-Synuclein Clearance

Relationship to GBA and Lysosomal PD

PD Substantia Nigra Findings

Role in Amyotrophic Lateral Sclerosis

TDP-43 Pathology

Motor Neuron Vulnerability

ALS Genetics Connection

Neuronal Ceroid Lipofuscinosis Type 10 (CLN10)

Disease Overview

Molecular Mechanism

Diagnosis and Management

Therapeutic Strategies

Enhancement of Cathepsin D Activity

Cathepsin D Inhibitors

Substrate Reduction Approaches

Expression Patterns

Molecular Interactions

Substrates

Protein Interactions

Biomarker Potential

Research Models

Cell Culture

Animal Models

Chemical/Induced Models

See Also

External Links

References

💬 Discussion